- Home
- JHS vs GNLX Comparison
JHS vs GNLX Comparison
Compare JHS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- GNLX
- Stock Information
- Founded
- JHS 1973
- GNLX 2001
- Country
- JHS United States
- GNLX United States
- Employees
- JHS N/A
- GNLX N/A
- Industry
- JHS Finance Companies
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- JHS Finance
- GNLX Health Care
- Exchange
- JHS Nasdaq
- GNLX Nasdaq
- Market Cap
- JHS 131.4M
- GNLX 128.0M
- IPO Year
- JHS N/A
- GNLX 2023
- Fundamental
- Price
- JHS $11.46
- GNLX $3.34
- Analyst Decision
- JHS
- GNLX Strong Buy
- Analyst Count
- JHS 0
- GNLX 5
- Target Price
- JHS N/A
- GNLX $16.20
- AVG Volume (30 Days)
- JHS 32.8K
- GNLX 138.9K
- Earning Date
- JHS 01-01-0001
- GNLX 08-07-2025
- Dividend Yield
- JHS 3.96%
- GNLX N/A
- EPS Growth
- JHS N/A
- GNLX N/A
- EPS
- JHS 0.02
- GNLX N/A
- Revenue
- JHS N/A
- GNLX N/A
- Revenue This Year
- JHS N/A
- GNLX N/A
- Revenue Next Year
- JHS N/A
- GNLX N/A
- P/E Ratio
- JHS $553.50
- GNLX N/A
- Revenue Growth
- JHS N/A
- GNLX N/A
- 52 Week Low
- JHS $9.76
- GNLX $1.83
- 52 Week High
- JHS $11.25
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- JHS 67.19
- GNLX 50.37
- Support Level
- JHS $11.30
- GNLX $3.32
- Resistance Level
- JHS $11.38
- GNLX $3.62
- Average True Range (ATR)
- JHS 0.06
- GNLX 0.24
- MACD
- JHS 0.01
- GNLX -0.02
- Stochastic Oscillator
- JHS 87.54
- GNLX 23.40
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.